Local Anesthetic
Exparel for Craniofacial Pain
This trial tests if injecting Exparel into the nasal area can help people with craniofacial pain. Exparel is a long-lasting pain reliever, and the study focuses on those who usually get pain relief from Lidocaine during ENT procedures.
Procedure
Lidocaine Patch for Peripheral Neuropathy
This trial will compare a lidocaine patch to a placebo patch to see if the lidocaine patch helps reduce neuropathic pain. Measurements and a visual scale will track pain severity. The study will also assess a hybrid biomarker to distinguish between active and placebo treatments.
Focused Ultrasound
Focused Ultrasound for Trigeminal Neuralgia
This trial is testing a new, non-invasive way to treat Trigeminal Neuralgia that uses ultrasound waves to target and heat up the pain-conducting nerves. The goal is to see if this treatment is safe and effective.
Behavioural Intervention
Exercise Intervention for Neuropathic Pain After Spinal Cord Injury
This trial is studying how functional electrical stimulation (FES) can help people with spinal cord injuries by reducing pain, improving brain function, and increasing the size of the hippocampus.
Deep Brain Stimulation
DBS for Chronic Pain
This trial is testing a new way to provide deep brain stimulation (DBS) for people with chronic pain that has not been relieved by other treatments. DBS involves surgically placing a small device in the brain that sends electrical signals to specific areas. The goal of this trial is to find out whether DBS is more effective when it is turned on only when needed, rather than continuously.
Popular Filters
Trials for Nerve Pain Patients
Behavioural Intervention
Virtual Reality Self-Hypnosis for Pain Relief
This trial is looking at whether a self-hypnosis software, used with a virtual reality device, can help to relieve pain in HIV patients. The study will assess the safety, usability, and effectiveness
Anti-epileptic drug
Gabapentin for Neuropathic Pain in Children
This trial aims to determine how effective gabapentin is in reducing and resolving pain in children with severe brain-based developmental disabilities. These children often experience unexplained periods of pain and irritability, and the
Procedure
Focused Ultrasound for Neuropathic Pain
This trial is testing a new treatment that uses sound waves directed at specific parts of the brain to help reduce pain. It targets patients with ongoing neuropathic pain that hasn't been managed well by other treatments. The sound waves aim to improve the function of brain areas that process pain signals. This noninvasive treatment option has shown promise in treating chronic neuropathic pain.
Trials for Diabetic Neuropathy Patients
Procedure
Tetrodotoxin for Chemotherapy-Induced Neuropathic Pain
This trial is testing the effects of the study drug on neuropathic pain caused by chemotherapy. It will last 13 weeks and participants will be randomly assigned to either the study drug or placebo group.
Cannabinoid
Cannabis Derivatives for Diabetic Neuropathy
This trial tests if cannabis derivatives (THC, CBD, and their combination) can reduce chronic diabetic nerve pain in Veterans. Veterans often don't get enough relief from standard treatments, so this study aims to find out if cannabis can help. The trial will test if these cannabis compounds are effective. Cannabis has been studied for its potential to alleviate pain in various conditions, including diabetic neuropathy, but its long-term safety and efficacy remain uncertain.
Neurostimulation Device
Micro-Implantable Pulse Generator for Chronic Pain
This trial is testing whether adding peripheral nerve stimulation to conventional medical management is more effective and safe than just using conventional medical management for chronic, intractable peripheral neuralgia that is of post-traumatic or post-surgical origin.
Non-invasive Brain Stimulation
Noninvasive Brain Stimulation for Diabetic Neuropathy
This trial is testing a new treatment called non-invasive brain stimulation (ESSTim) for people with pain from diabetic neuropathy. The treatment uses mild electrical signals to change how the brain processes pain. Researchers believe this could be more effective. Non-invasive brain stimulation techniques have been explored for their potential to reduce chronic pain by altering brain activity.
Phase 3 Trials
Topical Analgesic
High-Dose vs Low-Dose Capsaicin for Neuropathic Pain
This trial is testing a new topical pain medication against a low-dose capsaicin control to see if it is more effective and safe in treating moderate to severe post-surgical neuropathic pain.
Glutamate Receptor Antagonist
Basimglurant for Trigeminal Neuralgia
This trial is testing a medication called basimglurant to see if it can help reduce severe facial pain in adults with Trigeminal Neuralgia. The medication works by blocking a specific receptor in the nervous system to lower pain signals. Researchers will measure changes in pain using patient diaries and feedback.
Antiepileptic
Brivaracetam for Neuropathic Pain in SCI
This trial is testing brivaracetam, a medication that may help reduce severe pain in people with spinal cord injuries. It targets a specific protein in the spinal cord that is linked to pain. The study aims to see if this treatment is effective for those who do not respond well to other pain medications.
Trials With No Placebo
Behavioural Intervention
Virtual Reality Self-Hypnosis for Pain Relief
This trial is looking at whether a self-hypnosis software, used with a virtual reality device, can help to relieve pain in HIV patients. The study will assess the safety, usability, and effectiveness
Topical Analgesic
High-Dose vs Low-Dose Capsaicin for Neuropathic Pain
This trial is testing a new topical pain medication against a low-dose capsaicin control to see if it is more effective and safe in treating moderate to severe post-surgical neuropathic pain.
NMDA Receptor Antagonist
Ketamine Infusion for Neuralgia
This trial is testing if giving ketamine can help reduce severe nerve pain in patients with brachial plexus injuries. Ketamine works by blocking pain signals to the brain. The study aims to see if this reduces the need for other pain medications. Ketamine has been reported to enhance the pain-relieving effects of local anesthetics and is used primarily for patients who are tolerant to opioids and those with severe acute pain.
Behavioural Intervention
Scrambler Therapy for Neuropathic Pain
This trial tests if Scrambler Therapy can reduce pain in patients with corticobasal syndrome. The therapy uses electrical signals to trick the brain into feeling non-painful sensations instead of pain. The goal is to see if this treatment can lower pain levels significantly over a short period. Scrambler Therapy is a noninvasive technique that substitutes pain information with non-painful sensations.
View More Related Trials
Frequently Asked Questions
Introduction to neuropathic pain
What are the top hospitals conducting neuropathic pain research?
When it comes to finding new solutions for those suffering from neuropathic pain, several top hospitals are leading the way. Stanford University, located in both Stanford and Palo Alto, California, is at the forefront of this field with a total of five active neuropathic pain trials between its two campuses. Since recording their first trial in 2016 (Stanford) and 2022 (Palo Alto), they have demonstrated a commitment to advancing our understanding of this condition. Meanwhile, in Miami, Florida, the University of Miami has also emerged as an influential institution with three ongoing neuropathic pain trials and a record of four completed studies since initiating their first trial in 2017.
Heading north to Minneapolis, Minnesota, we find another prestigious facility making strides in neuropathic pain research. The University of Minnesota has successfully conducted five clinical trials on this subject thus far while currently running three more investigations. Their dedication began in 2016 when they embarked on their inaugural neuropathic pain study. Rounding off these pioneering hospitals is Massachusetts General Hospital in Boston—this renowned establishment has made significant contributions to addressing neuropathic pain through six completed clinical trials and continues their efforts with three ongoing studies since delving into this area back in2006.
These medical centers collectively represent beacons of hope for individuals enduring the challenges posed by chronic neuropathic pain—a condition that can greatly affect one's quality life.Through innovative research endeavors carried out across different locations nationwide,a shared goal remains: alleviating suffering,promoting better treatments,and improving overall well-being.As these institutions push boundaries and expand knowledge about managing patients' conditions,the potential for breakthroughs emerges ever closer,fueling optimism among countless individuals who eagerly await advancements that might transform their lives forever
Which are the best cities for neuropathic pain clinical trials?
In the realm of neuropathic pain clinical trials, several cities stand out as leading centers for research. Among them are Boston, Massachusetts with 11 active trials investigating treatments like Gabapentin and Qutenza (capsaicin) 8% topical system. Houston, Texas also joins the ranks with 10 ongoing studies focused on interventions such as Tetrodotoxin for injection. Additionally, Miami, Florida contributes to the field with 8 active trials exploring innovative solutions like Transcranial direct electrical stimulation (tDCS). These cities serve as key hubs where individuals suffering from neuropathic pain can find opportunities to participate in cutting-edge clinical trials that could potentially revolutionize treatment options and improve their quality of life.
Which are the top treatments for neuropathic pain being explored in clinical trials?
Clinical trials investigating treatments for neuropathic pain have identified several promising options. [18F]FTC-146, a drug first listed in 2018, is currently being explored in two active trials dedicated to neuropathic pain. Another effective approach is spinal cord stimulation, which has shown positive results in five all-time trials and is currently under investigation in two ongoing studies. Additionally, ketamine infusion therapy has emerged as a potential treatment option with one active trial and one all-time trial focused on neuropathic pain since its recent introduction in 2021. These innovative approaches offer hope for individuals suffering from this challenging condition.
What are the most recent clinical trials for neuropathic pain?
Exciting developments are underway in the field of neuropathic pain management, with recent clinical trials offering potential breakthroughs. One such trial explores the effectiveness of RTA 901 Dose 1 as a treatment for neuropathic pain. Additionally, Gabapentin has shown promising results in Phase 3 trials, indicating its potential to provide relief for individuals suffering from this condition. Another avenue being explored is the use of THC (Dronabinol) and CBD/PEA as alternative therapies for neuropathic pain management. Moreover, AFA-281 shows promise in early-phase studies as a potential solution to alleviate neuropathic pain symptoms. These ongoing trials hold great promise and offer hope to those experiencing the debilitating effects of neuropathy-related discomfort.
What neuropathic pain clinical trials were recently completed?
In recent years, numerous clinical trials have been conducted to explore potential treatments for neuropathic pain. Notable among these trials are the completion of a study on LY3526318 by Eli Lilly and Company in January 2022. In December 2020, Lexicon Pharmaceuticals concluded their trial on LX9211, while Eliem Therapeutics (UK) Ltd. completed a trial on ETX-018810 in November of the same year. Other completed trials include studies on Naloxone Hydrochloride 0.4 MG/ML by Seema Capoor in October 2020, Galcanezumab by Duke University and BAY1817080 by Bayer both in July 2020, as well as LY3016859 and LX9211 high dose by Eli Lilly and Company and Lexicon Pharmaceuticals respectively also in July 2020. Furthermore, Aptinyx finalized a trial on NYX-2925 at a dosage of 50 mg back in November 2019. These collective efforts reflect the ongoing commitment to finding effective therapies for patients suffering from neuropathic pain.